Anti-Kickback Statute: DOJ’s Corporate Arsenal Grows Stronger

February 12, 2025  |  New York Law Journal

A recent Second Circuit ruling underscores the risks health care companies face in paying doctors for speaker programs and conducting business entertainment commonplace in other industries.  The decision in U.S. ex rel Camburn v. Novartis Pharmaceuticals lowers the bar for Anti-Kickback Statute liability, broadening potential criminal exposure and making it easier for whistleblowers and the DOJ to pursue civil remedies under the False Claims Act, even when payments can be seen to serve legitimate purposes.  In their latest article for the NYLJ, “Anti-Kickback Statute: DOJ’s Corporate Arsenal Grows Stronger” Morvillo Abramowitz Grand Iason & Anello partners Robert J. Anello and Richard F. Albert break down how the Second Circuit’s ruling expands enforcement risk in the healthcare industry.

Anti-Kickback Statute: DOJ’s Corporate Arsenal Grows Stronger (pdf | 239.62 KB)